Professional
Added to YB: 2025-03-21
Pitch date: 2024-12-31
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
+12.13%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$403.14
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
growth
Show full summary:
Parnassus Core Equity Fund New Position: Vertex Pharmaceuticals Incorporated
VRTX (new position): High-quality biotech with strong management. Promising acquisition and advanced diabetes pipeline. Innovative approach and management expected to achieve positive clinical outcomes, strengthening competitive advantage.
Read full article (1 min)